ID Source | ID |
---|---|
PubMed CID | 6702 |
CHEMBL ID | 1413787 |
CHEBI ID | 82382 |
SCHEMBL ID | 591041 |
MeSH ID | M0105277 |
Synonym |
---|
BIDD:GT0778 |
disperse |
smr001224475 |
MLS002152851 , |
9,10-anthracenedione, 1-amino-2-methyl- |
nci-c01901 |
celliton orange r |
nsc39943 |
disperse orange |
2-methyl-1-anthraquinonylamine |
microsetile orange ra |
acetate fast orange r |
nsc-39943 |
supracet orange r |
perliton orange 3r |
82-28-0 |
nyloquinone orange jr |
cilla orange r |
c.i. 60700 |
disperse orange (anthraquinone dye) |
9, 1-amino-2-methyl- |
duranol orange g |
acetoquinone light orange jl |
c.i. disperse orange 11 |
serisol orange yl |
1-amino-2-methylanthraquinone |
wln: l c666 bv ivj dz e1 |
artisil orange 3rp |
anthraquinone, 1-amino-2-methyl- |
1-amino-2-methylanthracene-9,10-dione |
nsc-667744 |
NCGC00091244-01 |
EU-0047978 |
disperse orange (van) |
disperse orange 11 |
1-amino-2-methyl-9,10-anthracenedione |
hsdb 4101 |
ccris 32 |
ci 60700 |
ci disperse orange 11 |
nsc 39943 |
1-amino-2-methylanthra-9,10-quinone |
einecs 201-408-3 |
brn 0650595 |
nsc 667744 |
oranz disperzni 11 [czech] |
1-amino-2-methyl-9,10-anthraquinone |
1-amino-2-methyl-anthracene-9,10-dione |
nsc667744 |
1-amino-2-methyl-anthraquinone |
NCGC00091244-02 |
A1255 |
STK803591 |
AKOS000120131 |
NCGC00091244-03 |
C19320 |
dtxsid7020057 , |
cas-82-28-0 |
tox21_302964 |
dtxcid9057 |
NCGC00256386-01 |
tox21_201681 |
NCGC00259230-01 |
BBL013160 |
FT-0683766 |
oranz disperzni 11 |
4-14-00-00496 (beilstein handbook reference) |
unii-rhn157f30q |
rhn157f30q , |
1-amino-2-methylanthraquinone [hsdb] |
1-amino-2-methylanthraquinone [iarc] |
c.i. solvent orange 35 |
amino-2-methylanthraquinone, 1- |
SCHEMBL591041 |
CHEBI:82382 , |
bdbm76758 |
cid_6702 |
1-azanyl-2-methyl-anthracene-9,10-dione |
1-amino-2-methylanthra-9,10-quinone # |
1-amino-2-methyl-9,10-dihydroanthracene-9,10-dione |
CHEMBL1413787 |
mfcd00001220 |
disperse orange 11, analytical standard |
Z57210133 |
Q27155911 |
VS-03694 |
1-amino-2-methyl anthraquinone |
disperse orange 11 100 microg/ml in acetonitrile |
D88403 |
EN300-18148 |
CS-W020940 |
Class | Description |
---|---|
anthraquinone | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 8.9125 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 4.6145 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 10.0000 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 36.2529 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.8583 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 13.7726 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 10.3225 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 2.7222 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 7.9324 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743054 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 22.3872 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 17.0364 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 3.1623 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 24.0645 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 5.5476 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 7.6099 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 22.7338 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 2.6927 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 12.6611 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 34.6697 | 0.3758 | 27.4851 | 61.6524 | AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 13.5108 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.1317 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID588514; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091 |
67.9K protein | Vaccinia virus | Potency | 10.0000 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 35.4813 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
P53 | Homo sapiens (human) | Potency | 56.2341 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 2.5119 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 24.5442 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
caspase-3 | Homo sapiens (human) | Potency | 17.0364 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
IDH1 | Homo sapiens (human) | Potency | 23.1093 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 10.3663 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.5987 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 56.0500 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
hemoglobin subunit beta | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 9.0861 | 31.6228 | AID925 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0631 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.5387 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 8.0338 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0398 | 16.7842 | 39.8107 | AID995 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 25.1189 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 0.7079 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 10.2609 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 5.0119 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 14.1254 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
plasminogen precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 39.8107 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 0.2311 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 2.3211 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 51.2908 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 2.3211 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 1.8834 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 1.0000 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 13.4534 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 11.6105 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
SUMO-1-specific protease | Homo sapiens (human) | IC50 (µMol) | 42.3000 | 0.8050 | 19.3461 | 87.7000 | AID488921 |
SUMO1/sentrin specific peptidase 7 | Homo sapiens (human) | IC50 (µMol) | 4.3300 | 1.6400 | 7.2648 | 23.9000 | AID488904 |
caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 11.8000 | 0.0256 | 20.3235 | 74.3000 | AID488901 |
sentrin-specific protease 8 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0408 | 18.9292 | 94.8000 | AID488903 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glycogen synthase kinase-3 alpha | Homo sapiens (human) | AC50 | 300.0000 | 0.0135 | 29.7434 | 171.7000 | AID463203 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.22) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |